Education
About Us
Working with TipRanks
Follow Us
Talphera (TLPH)
NASDAQ:TLPH
TLPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.38 - $1.19
Previous CloseN/A
Volume42.81K
Average Volume (3M)2.29M
Market Cap
$10.58M
Enterprise Value$15.60M
Total Cash (Recent Filing)$6.79M
Total Debt (Recent Filing)$6.50M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Nov 17, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding20,522,655
10 Day Avg. Volume438,540
30 Day Avg. Volume2,290,982
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.47
Enterprise Value/Revenue577.74
Enterprise Value/Gross Profit11.85
Enterprise Value/Ebitda-1.37
Forecast
1Y Price Target
$3.00Price Target Upside445.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Investor ConfidencePrivate investors, including Nantahala Capital, are supportive and may waive the share price requirement for further financing, reflecting investor confidence.
Regulatory ApprovalTalphera recently received FDA approval to offer Niyad to patients in a compassionate use program.
Trial EnrollmentRecent sites have been enrolling patients faster and more steadily than prior sites, indicating a positive trend for the trial's progress.
Bears Say
Patient EnrollmentPatient enrollment for the NEPHRO CRRT study has been sluggish, with only six patients enrolled since November 2024.
Talphera News
TLPH FAQ
What was Talphera’s price range in the past 12 months?
Talphera lowest stock price was $0.38 and its highest was $1.19 in the past 12 months.
What is Talphera’s market cap?
Talphera’s market cap is $10.58M.
When is Talphera’s upcoming earnings report date?
Talphera’s upcoming earnings report date is Nov 17, 2025 which is in 71 days.
How were Talphera’s earnings last quarter?
Talphera released its earnings results on Aug 14, 2025. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.13 by $0.03.
Is Talphera overvalued?
According to Wall Street analysts Talphera’s price is currently Undervalued.
Does Talphera pay dividends?
Talphera does not currently pay dividends.
What is Talphera’s EPS estimate?
Talphera’s EPS estimate is -0.13.
How many shares outstanding does Talphera have?
Talphera has 20,522,655 shares outstanding.
What happened to Talphera’s price movement after its last earnings report?
Talphera reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.13. Following the earnings report the stock price went down -2.326%.
Which hedge fund is a major shareholder of Talphera?
Currently, no hedge funds are holding shares in TLPH
Company Description
Talphera
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.
TLPH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook due to the significant progress in accelerating NEPHRO study enrollment, reducing cash operating expenses, and advancing regulatory interactions. However, challenges with supply chain issues and reliance on future financing were noted. Despite these challenges, the overall sentiment is positive due to the significant progress and strategic adjustments made.View all TLPH earnings summariesTLPH Stock 12 Month Forecast
Average Price Target
$3.00
▲(445.45% Upside)
Technical Analysis
Ownership Overview
12.70% Insiders
1.88% Mutual Funds
25.08% Other Institutional Investors
60.06% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---